Edgar Filing: ILLUMINA INC

ILLUMINA, INC.

Date: February 1, 2016

/s/ Charles E. Dadswell

Charles E. Dadswell

Senior Vice President, General Counsel and Secretary

8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15 (d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): January 28, 2016

Illumina, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-35406

33-0804655

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)


5200 Illumina Way, San Diego, California		92122
(Address of principal executive offices)		(Zip Code)

(858) 202-4500

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

5.02(b)

On January 28, 2016, Jay T. Flatley, Chief Executive Officer of Illumina, Inc., was elected Chairman of the Board of Directors (the “Board”) following the resignation of William H. Rastetter, Ph.D. The Board intends to appoint a lead independent director.

Dr. Rastetter stepped off the Board after 17 years of service as a Board member and 11 years as Chairman, in compliance with Illumina governance practices, in order to invest in and serve as an Illumina representative on the board of directors of GRAIL, Inc. GRAIL is Illumina’s majority-owned subsidiary formed to enable cancer screening from a simple blood test powered by Illumina sequencing technology.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.